Search clinical trials for: NK immunotherapy

Total 5480 results

23andMe, Inc.

Recruiting

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

Solid Tumor

United States
Ryan Stephenson

Recruiting

Naltrexone and Propranolol Combined With Immunotherapy

Advanced Melanoma

United States
Antonio Pérez Martínez

Recruiting

Clinical Trial of Infusion of Activated NK Cells for the Treatment of Sarcomas (SANKOMA)

Malignant Sarcoma

Spain
Nielsen BioSciences, Inc.

Recruiting

Candin for the Treatment of Common Warts

Common Warts (Verruca Vulgaris)

United States
Hong Kong Children's Hospital
The University of Hong Kong

Recruiting

Quadruple Immunotherapy for Neuroblastoma

Neuroblastoma Recurrent

Hong Kong
AbelZeta, Inc.
Nektar Therapeutics

Recruiting

C-TIL051 in Non-Small Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States
Nektar Therapeutics

Recruiting

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Non-Hodgkin Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma

United States
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Multiple Myeloma | Immunotherapy

China
Nationwide Children's Hospital
National Pediatric Cancer Foundation

Recruiting

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue (TINKS)

Pediatric Sarcoma, Refractory | Pediatric Sarcoma, Relapsed

United States
Dragonfly Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of DF9001 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Xinxiang medical university

Recruiting

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Relapsed/Refractory Solid Tumors

China
ETOP IBCSG Partners Foundation
USZ Foundation

Recruiting

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (USZ-STRIKE)

Melanoma | Non-Small Cell Lung Cancer

Switzerland, Netherlands, Italy, United Kingdom
Novartis Pharmaceuticals

Recruiting

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Squamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma

Japan, France, Italy, Spain, Belgium, Germany, Taiwan, United States, Singapore
Belarusian Research Center for Pediatric Oncology...

Recruiting

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Acute Myeloid Leukemia

Belarus
German Cancer Research Center

Not yet recruiting

Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia (NAKIP-AML)

Acute Myeloid Leukemia
Belarusian Research Center for Pediatric Oncology...

Recruiting

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML

Acute Myeloid Leukemia

Belarus
Fudan University
KAEDI

Recruiting

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Glioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon Cancer

China
Nkarta Inc.

Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Lymphoma, Non-Hodgkin | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | B-cell Acute Lymphoblastic Leukemia | Small Lymphocytic Lymphoma | Large B-cell Lymphoma | Indolent Lymphoma | Aggressive Lymphoma | Large-cell Lymphoma

United States, Australia
National Cancer Institute (NCI)

Recruiting

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Gastroesophageal Junction (GEJ) Cancers | Advanced HNSCC

United States
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico
Artiva Biotherapeutics, Inc.

Recruiting

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States
Biohaven Pharmaceuticals, Inc.
Dana-Farber Cancer Institute

Recruiting

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients

Multiple Myeloma

United States
Glycostem Therapeutics BV

Recruiting

A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Belgium, Netherlands, Switzerland, France, Germany
The Netherlands Cancer Institute

Recruiting

Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE)

Cutaneous Squamous Cell Carcinoma

Netherlands
Rong Tao

Recruiting

Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Radboud University Medical Center
Dutch Cancer Society

Recruiting

Natural Killer-cell Therapy for Acute Myeloid Leukemia (NK4AML)

Acute Myeloid Leukemia Refractory | Acute Myeloid Leukemia, Relapsed, Adult

Netherlands
University Medical Center Groningen

Recruiting

POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors (POINTING)

Melanoma | Non-Small Cell Lung Cancer

Netherlands
Dragonfly Therapeutics

Recruiting

Study of DF1001 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States, Denmark, Netherlands, Belgium, France
Second Affiliated Hospital of Guangzhou Medical...
Hunan Zhaotai Yongren Medical Innovation Co. Ltd.

Recruiting

Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

Anti-cancer Cell Immunotherapy | T Cell and NK Cell

China
Vall d'Hebron Institute of Oncology
Taisho Pharmaceutical Co., Ltd.; Roche Pharma AG; Iqvia Pty Ltd; Janssen, LP

Recruiting

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)

Advanced Solid Tumor

Spain, France, Germany, Netherlands, Sweden, United Kingdom, Italy
Maastricht University Medical Center
KU Leuven; University College, London; Erasmus Medical Center; Catholic University... and other collaborators

Recruiting

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study (IMMUNOSABR2)

NSCLC Stage IV | Metastatic Disease

Belgium, Netherlands, United Kingdom, France, Germany, Italy
Celyad Oncology SA

Recruiting

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)

Unresectable Metastatic Colorectal Cancer

Belgium, United States
University Hospital, Basel, Switzerland

Recruiting

Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Switzerland
National Cancer Institute (NCI)

Completed

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

Sarcoma | Neuroblastoma | Solid Tumors | Brain Tumors | Pediatric Cancers

United States
M.D. Anderson Cancer Center

Suspended

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Colon Cancer | Resected Stage

United States
Technical University of Munich

Completed

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

NSCLC Stage IIIA/B

Germany
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City; Celldex Therapeutics and other collaborators

Completed

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)

Metastatic Castration-resistant Prostate Cancer

United States
Nkarta Inc.

Active, not recruiting

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

MDS | AML, Adult | Relapsed/Refractory AML | Refractory Myelodysplastic Syndromes

United States
University of Wisconsin, Madison
Nektar Therapeutics

Terminated

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Cytovation AS
Merck Sharp & Dohme LLC

Active, not recruiting

CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (CICILIA)

Advanced Solid Tumor Malignancy

Netherlands, France, Spain
Monica Thakar

Completed

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | CNS Tumors

United States
Cytovation AS
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst)

Advanced Breast Cancer | Advanced Melanoma | Advanced Head and Neck Squamous Cell Carcinoma

United States, France, Italy, Spain, Netherlands
The Netherlands Cancer Institute

Completed

ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (IMCISION)

Head and Neck Neoplasms | Immunotherapy

Netherlands
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
New Approaches to Neuroblastoma Therapy Consortium
Nationwide Children's Hospital; United Therapeutics

Active, not recruiting

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Neuroblastoma

United States
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bladder Cancer | Bladder Tumor | Muscle-Invasive Bladder Cancer

Russian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
Fate Therapeutics

Terminated

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Xinxiang medical university

Completed

CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma

Non-small Cell Lung Cancer

China
NKGen Biotech, Inc.

Active, not recruiting

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer | Unresectable Carcinoma

United States
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States

Search clinical trials for: NK immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations